Risks and Returns of Verona Pharma Plc ADR (VRNA) Stock
Jefferies raised the price target for the Verona Pharma Plc ADR (NASDAQ:VRNA) stock to “a Buy”. The rating was released on May 22, 2023, according to finviz. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $31. The stock was initiated by H.C. Wainwright, who disclosed […]
It’s not the right time to quit: Verona Pharma Plc ADR (VRNA) Stock
Jefferies raised the price target for the Verona Pharma Plc ADR (NASDAQ:VRNA) stock to “a Buy”. The rating was released on May 22, 2023, according to finviz. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $31. The stock was initiated by H.C. Wainwright, who disclosed […]
What does the future hold for Verona Pharma Plc ADR (VRNA) Stock?
Jefferies raised the price target for the Verona Pharma Plc ADR (NASDAQ:VRNA) stock to “a Buy”. The rating was released on May 22, 2023, according to finviz. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $31. The stock was initiated by H.C. Wainwright, who disclosed […]
What are the chances of Verona Pharma Plc ADR (VRNA) Stock turning the corner?
Jefferies raised the price target for the Verona Pharma Plc ADR (NASDAQ:VRNA) stock to “a Buy”. The rating was released on May 22, 2023, according to finviz. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $31. The stock was initiated by H.C. Wainwright, who disclosed […]
Verona Pharma Plc ADR (NASDAQ:VRNA) Stock is trading Below -2.42% From 50-Day SMA
Jefferies raised the price target for the Verona Pharma Plc ADR (NASDAQ:VRNA) stock to “a Buy”. The rating was released on May 22, 2023, according to finviz. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $31. The stock was initiated by H.C. Wainwright, who disclosed […]
Invest in Verona Pharma Plc ADR (VRNA) Stock with the prospect of future returns
Jefferies raised the price target for the Verona Pharma Plc ADR (NASDAQ:VRNA) stock to “a Buy”. The rating was released on May 22, 2023, according to finviz. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $31. The stock was initiated by H.C. Wainwright, who disclosed […]
